Insmed (NASDAQ:INSM) CEO William Lewis Sells 21,398 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 21,398 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $103.32, for a total value of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This trade represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Wednesday, June 3rd, William Lewis sold 7,605 shares of Insmed stock. The stock was sold at an average price of $102.27, for a total transaction of $777,763.35.
• On Thursday, April 16th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03.
• On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total transaction of $1,746,290.78.

Insmed Trading Down 1.0%

Shares of INSM stock opened at $103.38 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The stock has a market capitalization of $22.41 billion, a P/E ratio of -17.98 and a beta of 0.79. The company has a 50 day moving average price of $112.90 and a 200 day moving average price of $143.82. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same period in the prior year, the firm earned ($1.42) EPS. The firm’s revenue for the quarter was up 229.7% on a year-over-year basis. Equities research analysts predict that Insmed, Inc. will post -2.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INSM. Barclays increased their price objective on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Raymond James Financial assumed coverage on Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Finally, Roth Mkm reiterated a “buy” rating on shares of Insmed in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $211.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. CoreCap Advisors LLC acquired a new position in Insmed in the fourth quarter valued at approximately $27,000. Reflection Asset Management purchased a new stake in shares of Insmed during the 4th quarter worth approximately $30,000. GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter worth approximately $30,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Insmed in the 4th quarter valued at $32,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.